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Abstract
Background: Anti-glomerular basement membrane (GBM) antibodies are highly specific for Goodpasture’s or
anti-GBM disease, in which they are generally directed against the non-collagenous (NC1) domain of the alpha 3
chain of type IV collagen(α3(IV)), and less commonly, toward the α 4(IV) or α 5(IV) chains, which form a triple helical
structure in GBM and alveolar basement membrane (ABM). Alterations in the hexameric structure of the NC1 (α3
(IV)), allows novel epitopes to be exposed and an immune response to develop, with subsequent linear antibody
deposition along the GBM, leading to a crescentic glomerulonephritis. Positive anti-GBM antibodies are assumed to be
pathogenic and capable of binding GBM in vivo, especially in the context of rapidly progressive glomerulonephritis.
We have investigated patients with circulating anti-GBM antibodies, reactive to α3 (IV) and human GBM by
immunoassays and Western blotting respectively, with focal necrotising crescentic glomerulonephritis but no linear
GBM antibody deposition on immunohistochemistry. Three out of four were also ANCA positive. Despite not binding
native GBM, patients’ sera showed linear binding to primate glomeruli by indirect immunofluorescence, in the 2 cases
tested. Following treatment, significant improvements in kidney function were found in 3/4 patients.
Case presentation: We present four patients with crescentic glomerulonephritis and circulating anti-GBM antibodies,
but no glomerular binding.
Conclusions: These novel findings, demonstrate that in some patients anti-GBM antibodies may not bind their own GBM.
This has important implications for clinical diagnosis, suggesting that histological confirmation of kidney injury by anti-GBM
antibodies should be obtained, as non-binding GBM antibodies may be associated with significant renal recovery.
Keywords: Goodpasture’s disease, Anti- glomerular basement membrane antibodies, ANCA, Linear binding,
Glomerulonephritis
Background
Anti-GBM antibodies, are highly specific and sensitive
for Goodpasture’s (anti-GBM) disease [1]. Antibodies are
generally directed against the NC1 domain of the alpha
3 chain of type IV collagen(α3 (IV)) and less commonly,
toward the α 4(IV) or α 5(IV) chains, which together
form a triple helical structure in glomerular and alveolar
basement membranes. Anti-GBM disease typically
presents with a rapidly progressive crescentic glomerulo-
nephritis (CGN) and pulmonary haemorrhage in ap-
proximately half of the patients. Despite the high
specificity and sensitivity of the antibody tests, ‘false’
positive’ tests are reported in patients with polyclonal
immunoglobulin responses following viral infections or
drugs, but without CGN [2–4]. The gold standard for
diagnosis is the kidney biopsy, demonstrating diffuse
CGN with linear immunoglobulin staining along the
GBM. Linear GBM immunoglobulin binding is also
found in the elderly and in diabetic patients, although
not in the context of CGN possibly due to changes in
glycation patterns of the GBM antigens [5]. Additionally,
atypical cases of anti-GBM disease have been reported,
such as patients who lack circulating antibodies, detected
using conventional assays, but with linear glomerular de-
position on biopsy [6, 7], in some cases without CGN, in
others with mesangial proliferative or endocapillary glom-
erulonephritis [7]. Circulating anti-GBM antibodies are
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detected in approximately 5–10% of sera from patients
with anti-neutrophil cytoplasm antibody(ANCA) positive
vasculitis [1], in some at lower titre than in patients with
Goodpasture’s disease [1]. Experimental models have
shown that low dose anti-GBM antibodies, that them-
selves do not induce CGN, can synergise with ANCA to
augment glomerulonephritis, without development of
linear anti-GBM staining [8, 9]. The synergy is in part due
to increased production of glomerular cytokines and che-
mokines, as well as glomerular neutrophil activation. Here
we present a cohort of four patients with circulating
anti-GBM antibodies, two with high titre, and three with
low level ANCA, all with CGN and no evidence of linear
anti-GBM staining by immunohistochemistry or immuno-
fluorescence. In all cases, sera bound recombinant α3
(IV), and two that were tested bound collagenase solubi-
lised human GBM, while two also bound primate glom-
eruli. These data suggest that not all anti-GBM antibodies
have similar pathogenic potential because some cannot
bind their host GBM under normal circumstances.
Case presentation
Case 1
A 66 year old Caucasian woman, was admitted to hospital
with malaise, macroscopic haematuria and a petechial rash
on both thighs. Her past medical history included seronega-
tive rheumatoid arthritis and hypertension. Her kidney
function at that point was normal, with a creatinine of
73 μmol/l (eGFR > 60 mls/min/1.73m2, MDRD formula),
and there was no proteinuria. Investigations revealed nega-
tive ANA, ANCA, anti-GBM antibodies as well as hepatitis
B and C serology. A kidney biopsy showed mild focal tubu-
lar and interstitial scarring, suggestive of modest chronic is-
chaemic damage, but no significant glomerular lesion and
negative immunoperoxidase staining on formalin fixed tis-
sue for all immunoproteins. Rapid resolution of the rash
was seen following a course of high-dose prednisolone.
Four months following the discontinuation of prednisol-
one and after a flu like illness, the rash recurred, along with
macroscopic haematuria, malaise and anorexia. On admis-
sion, she had a blood pressure of 162/90 and a purpuric
rash over both thighs. Creatinine had risen to 241 μmol/L
(eGFR 18 mls/min/1.73m2). Haemoglobin 10.9 g/dL, CRP
138 mg/L. Urine protein: creatinine ratio (PCR) was ele-
vated at 150 mg/mmol; Tests revealed negative ANCA,
ANA and rheumatoid factor, normal levels of immunoglob-
ulins and complement. No anti-GBM antibody was ob-
tained at this time. A repeat kidney biopsy demonstrated a
severe, acute crescentic pauci-immune glomerulonephritis,
with evidence of moderate chronic kidney damage. 13/22
glomeruli showed evidence of vasculitic lesions, 3 were glo-
bally sclerosed and 6 were normal. Immunoperoxidase and
immunofluorescence were negative for IgG, IgM and IgA
and C3 (Fig. 1).
Treatment with intravenous methylprednisolone and
cyclophosphamide was commenced. An anti-GBM anti-
body titre, obtained 2 weeks post-discharge, was signifi-
cantly elevated at 359 IU/ml (NR 0–10, ELiA, Phadia
systems, Thermo Scientific). This elevation was con-
firmed on repeat testing. 14 cycles of plasma exchange
were performed with 6 doses of pulsed cyclophosphamide.
At four months creatinine was 130 μmol/l and at 4 years
105 μmol/l (eGFR 37 and 47 mls/min respectively)while
ANCA and anti-GBM have remained negative (Table 1).
Case 2
A 70 year old previously healthy Caucasian woman pre-
sented with lethargy, anorexia, nausea, vomiting, and a
two kilogram weight loss over the course of a fortnight.
Investigations showed an elevated serum creatinine of
477 μmol/L (eGFR 9 ml/min, CKD-EPI formula), with a
previous creatinine of 68 μmol/L (eGFR 91 ml/min) 3
months earlier. The blood pressure was 180/100 mmHg,
other physical findings were normal. Urinalysis revealed
blood and protein, while microscopy confirmed erythro-
cytes, leukocytes, dysmorphic red cells, but no red cell
casts. Serology showed positive MPO-ANCA with a titre
of 20 IU/ml (NR 0–5) and high titre anti-GBM antibody
titre > 200 IU/ml (NR 0–20; Alegria ELISA, Orgentec)
and 475 U/ml (using EliA Phadia assay), complement
levels were normal. Kidney function deteriorated over
the next few days, with creatinine reaching 809 μmol/l
(eGFR 5 ml/min). Kidney biopsy showed diffuse extraca-
pillary necrotizing glomerulonephritis, interstitial inflam-
mation and leucocytoclastic necrotizing vasculitis.
Immunohistochemistry on formalin fixed tissue showed
no immune deposits along the GBM (Fig. 2). She was
treated with methylprednisolone pulses, followed by oral
prednisolone. Haemodialysis and 7 plasma exchanges
were also initiated followed by intravenous cyclophospha-
mide. Although urine output improved, she remained
dialysis dependent and her repeat anti-GBM antibody
remained strongly positive. She therefore underwent 3
sessions of immunoabsoprtion on a protein A column
which led to a drop in anti-GBM titer from > 200 IU/l to
25 IU/l. Due to severe leucocytopenia with consecutive
pneumonia following the first dose of cyclophosphamide,
she was switched to weekly rituximab, which was also
stopped after the third dose following further infections.
Anti-GBM antibodies were negative at 4 months. She has
remained dialysis dependent 24 months later (Table 1).
Indirect immunofluorescence and western blotting
In order to test whether the anti-GBM antibodies were
capable of binding intact glomeruli, we used a validated
anti-GBM assay based on staining of monkey glomeruli
(Eurimmun GBM assay FA1250). Sections were incubated
with serum diluted 1:10 in PBS-Tween according to
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Fig. 1 Kidney biopsy section from Patient 1 showing (a) pauci-immune focal necrotising glomerulonephritis (H and E, × 400) and (b) negative
immunofluorescence for IgG (× 400); (c) A positive control showing linear IgG staining at identical exposure; (d) Indirect immunofluorescence
staining of patient sera on primate kidney; (e) positive control indirect immunofluorescence and (f) negative control indirect immunofluorescence.
Positive anti-glomerular basement membrane staining for IgG in a linear fashion was seen using the patient’s serum (× 400)
Table 1 Summary of patients with circulating anti-GBM antibodies without linear deposition
Age Gender Anti-GBM titre
at presentation
(NR < 10)
ANCA/Subtype/
titre
Peak creatinine
at presentation
(μmol/l)
Last follow
up creatinine
(μmol/l)
Time to anti-
GBM negativity/
months
Follow up/
months
Pulmonary
haemorrhage?
Treatment
66 F 359 Negative 271 105 4 50 N Prednisolone
Methylprednisolone
Cyclophosphamide
Plasma exchange
70 F 200 Yes/MPO/20 809 HD 4 24 N Methylprednisolone
Prednisolone
Plasma exchange
Cyclophosphamide
Immunoadsorption
Rituximab
79 F 28 Yes/MPO/33 446 199 2 18 N Methylprednisolone
Prednisolone
Rituximab
Cyclophosphamide
64 M 33 Yes/MPO/60 666 127 0.9 21 N Methylprednisolone
Plasma exchange
Prednisolone
Cyclophosphamide
Mycophenolate
mofetil
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manufacturer’s instructions. As expected the positive con-
trol samples stained with a linear pattern along the GBM,
while sera from patients 1 and 2 stained with a similar but
less intense pattern, suggesting that they were capable of
binding the exposed epitopes in a native glomerulus, but
not their own GBM (Figs. 1 and 2). Western blotting using
collagenase solubilised human GBM showed positivity
with 2/4 samples available (Additional file 1: Figure S1),
confirming the ability of the antibodies to bind human
collagenase solubilised GBM.
Case 3
A 64 year old man presented to a local community hos-
pital with a 5 week history of dry cough and fevers
which has persisted despite 2 courses of oral antibiotics.
There was a 10 year history of unclassified arthralgia.
Presenting creatinine was 682 μmol/L Urinalysis: 3 +
blood and protein. Urine microscopy revealed granular
casts with greater than 200 red cells/ cu.mm. Urinary
protein: creatinine (uPCR) ratio was 133 mg/mmol.
Physical examination was unremarkable, but BP 186/74
on admission. MPO-ANCA titre was 60 IU/ml (NR < 5)
and a positive anti-GBM titre of 33 IU/ml (NR < 10,
ELiA, Phadia systems). Complement levels normal.
Renal biopsy revealed crescentic glomerulonephritis in
80% of glomeruli. However, no glomerular deposition of
immunoglobulin or complement was seen on formalin
fixed tissue (Additional file 2: Figure S2). The patient
was treated with plasma exchange, pulsed methylpred-
nisolone, followed by oral prednisolone and six pulses
of intravenous cyclophosphamide. Maintenance ther-
apy was with a reducing course of prednisolone and
mycophenolate mofetil, due to azathioprine intolerance.
At 21 months of follow up serum creatinine was
127 μmol/L, and both MPO-ANCA and anti-GBM were
negative (Table 1).
Case 4
A 79 year old woman presented to a local hospital with
a 2 week history of epistaxis, arthralgia, weight loss and
Fig. 2 Kidney biopsy sections from patient 2 showing (a) focal necrotising crescentic glomerulonephritis (H and E × 200); (b) PAS stain of a
cellular crescent (× 400); Immunoperoxidase stains for (c) IgG and (d) C3; (e) Immunofluoresence for IgG (all × 400); (f) Indirect immunofluorescence
staining of patient sera on primate kidney
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anorexia. She gave a history of previous recurrent iritis,
with the last episode occurring 2 year prior to her pres-
entation. Physical examination was unremarkable apart
from peripheral oedema. Presenting creatinine was
430 μmol/L. Urine dipstick revealed + 3 blood and + 2
protein, and uPCR 259 mmol/mg. MPO-ANCA titer
was 33 IU/ml(NR < 5) and an anti-GBM titre of 28 IU/
ml(NR < 10, ELiA, Phadia systems). Renal biopsy re-
vealed a pauci-immune crescentic glomerulonephritis,
with no staining for IgG, IgA or IgM on formalin fixed
tissue. There was some chronic parenchymal damage
(Additional file 2: Figure S2). Treatment was with methyl-
prednisolone, a short course of oral prednisolone, rituxi-
mab and six pulses of intravenous cyclophosphamide. She
was also intolerant of maintenance azathioprine. Her
MPO-ANCA and anti-GBM titres remained < 1 IU/ml
and her creatinine was 199 μmol/L after 18 months’
follow-up (Table 1).
Discussion and conclusions
In this case series we present four patients with a
pauci-immune rapidly progressive glomerulonephritis
with anti-GBM antibodies, two with high titre, but
without linear deposition of antibody on the basement
membrane. The relevance of the anti-GBM antibodies in
such patients has not been focussed on previously.
While pauci-immune vasculitis lacking ANCA is a well-
recognised phenomenon representing between 27 and
38% of pauci-immune GN [10], none have been reported
with circulating anti-GBM antibodies.
All patients presented with non-specific prodromal
symptoms and significant kidney injury. In three out of
the four there was a substantial improvement in kidney
function following therapy, while one patient remained
dialysis dependant.
Anti-GBM antibodies are considered diagnostic for
Goodpasture’s disease and it has been suggested that the
level of anti-GBM antibodies correlates with long term
prognosis [11]. In addition, there are case reports of low
levels of anti-GBM antibodies being associated with an
indolent disease process [12]. Anti-GBM antibodies are
found in co-existence with ANCA [13] in up to 5% of
ANCA positive subjects and in one series all of the biop-
sied patients showed evidence of linear antibody depos-
ition [13]. It is notable that 18% of these double positive
patients reported were not biopsied, meaning that some
may have had lacked linear staining on the GBM as we
have described. Interestingly, none of the patients de-
scribed with creatinine levels > 500 μmol/ recovered
kidney function following immunosuppression with or
without adjunctive plasma exchange. This is in contrast
with our patients in whom kidney function recovery was
found in the majority.
All of our patients had binding to recombinant alpha3
(IV) collagen, and in both tested to collagenase solubi-
lised human GBM, demonstrating that these antibodies
were similar with those found in typical anti-GBM
disease. In addition, in 2 they bound primate kidney in a
linear fashion- another standardised assay for detecting
anti-GBM antibodies. Previous reports have shown that
in double positive(ANCA and anti-GBM antibody)
patients there may be a broader specificity to the
anti-GBM antibodies and that titres are lower than in
anti-GBM disease alone [14], however in two of our sub-
jects high anti-GBM titres were found.
The reason for the lack of linear binding in vivo is
intriguing, but the ability of the antibodies to bind fixed
primate kidney and collagenase digested human GBM,
suggests that one possible reason is that the patients do
not express the required epitope to allow antibody bind-
ing. In the native GBM, the cryptic nature of the anti-
genic epitopes is related to the quaternary structure of
the of alpha 3(IV) hexamers. Whilst autoantibodies can
bind some monomer containing hexamers (M-hexam-
ers), they cannot bind those containing both monomers
and dimers (D-hexamers) [15]. Alteration in the propor-
tion of M and D hexamers in the ABM is one possible
explanation for the variation in pulmonary haemorrhage
seen in some patients with Goodpasture’s disease [16]
and there may be a lack of exposure of the appropriate
M hexamers in our subjects’ GBM, preventing antibody
binding in vivo. This may also explain the cases of
anti-GBM antibody presenting with only pulmonary
haemorrhage [17]. Interestingly, in both of the patients
tested, binding to whole collagenase solubilised GBM
demonstrated binding to dimers only and not monomers
(Additional file 1: Figure S1). However, this raises the
question as to how the immune response to alpha3 (IV)
was generated initially, which may have involved some
degradation of GBM following the pauci-immune glom-
erular insult, or indeed exposure of epitopes from the
ABM. An experimental model in which T cell mediated
anti-GBM damage is induced without deposited anti-
bodies has been described, which may provide a poten-
tial disease mechanism [18]. Finally, there is the
possibility that the antigenic epitope or IgG were not
exposed by the standard histological processing follow-
ing collection of the sample into formalin, although they
were all treated in conventional ways, and both im-
munofluorescence and immunoperoxidase detection of
linear IgG were negative (Figs. 1-2 and Additional file 2:
Figure S2), while IgG staining of tubular protein droplets
and interstitial cells was observed making a processing
issue less likely (Additional file 3: Figure S3). These find-
ings have implications for clinical practice, suggesting we
should obtain histological confirmation of disease so that
patients can be appropriately counselled and managed.
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Additional files
Additional file 1: Figure S1. Western blot using whole human collagenase
solubilized GBM using positive control (patient with circulating anti-GBM
antibodies with linear glomerular binding and crescentic nephritis) and
patients 3 and 4, demonstrating binding to alpha 3 dimers and monomers
in the positive control but only dimers in patients 3 and 4. (PDF 18 kb)
Additional file 2: Figure S2. Renal biopsy sections from patients 3 and 4.
(TIF 1290 kb)
Additional file 3: Figure S3. IgG staining of biopsy from patient 4
showing protein droplets in renal tubular cells staining positive for IgG
and immunofluorescence of biopsy from patient 2 showing IgG staining
of interstitial cells. (TIF 869 kb)
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